Findings

What do systematic reviews say?

748 questions · 782 findings · 58 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 164 · 21%GRADE not reported 26 · 3.3%Very low 151 · 19.3%Low 222 · 28.4%Moderate 158 · 20.2%High 61 · 7.8%

Intervention not reported

5‐year overall survival rate (3 to 6 yr) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 5‐year overall survival rate (3 to 6 yr) (low certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 0.93 [0.84, 1.04]
2 studies · 912 participants
Low

Intervention not reported

10‐year overall survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 10‐year overall survival rate (5 to 15 yr) (moderate certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 0.79 [0.52, 1.2]
1 study · 430 participants
Moderate

Intervention not reported

5‐year disease specific survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 5‐year disease specific survival rate (5 to 15 yr) (moderate certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 0.95 [0.84, 1.07]
2 studies · 562 participants
Moderate

Intervention not reported

10‐year disease specific survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 10‐year disease specific survival rate (5 to 15 yr) (moderate certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 1.02 [0.88, 1.19]
1 study · 430 participants
Moderate

Intervention not reported

3‐year relapse‐free survive rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 3‐year relapse‐free survive rate (37.2/40.2 mo) (low certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 1.04 [0.71, 1.52]
1 study · 206 participants
Low

Intervention not reported

5‐year relapse‐free survive rate (66 mo) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 5‐year relapse‐free survive rate (66 mo) (low certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 0.96 [0.81, 1.14]
1 study · 132 participants
Low

Intervention not reported

3‐year local control rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 3‐year local control rate (37.2/40.2 mo) (low certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 0.95 [0.86, 1.05]
1 study · 206 participants
Low

Intervention not reported

5‐year local control rate (3 to 6 yr) · women with locally advanced uterine cervix cancer

The intervention showed no clear difference in 5‐year local control rate (3 to 6 yr) (low certainty).

1 finding from 1 review

High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer 2014 · Cochrane Headline outcomes only
RR 0.95 [0.87, 1.05]
1 study · 482 participants
Low

Intervention not reported

Overall Survival (median · Patients with brain metastases

The intervention showed no clear difference in overall Survival (median (low certainty).

1 finding from 1 review

Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
HR 1.11 [0.83, 1.48]
5 studies · 663 participants
Low

Intervention not reported

Progression free survival · Patients with brain metastases

The intervention showed no clear difference in progression free survival (low certainty).

1 finding from 1 review

Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
HR 0.76 [0.53, 1.1]
2 studies · 378 participants
Low

Intervention not reported

Any intracranial disease progression at 1 year · Patients with brain metastases

The intervention may leads to lower any intracranial disease progression at 1 year (low certainty).

1 finding from 1 review

Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
RR 0.46 [0.35, 0.6]
4 studies · 304 participants
Low

Intervention not reported

Neurocognitive function · Patients with brain metastases

1 finding from 1 review

Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 209 participants
Low

Intervention not reported

Health related quality of life · Patients with brain metastases

1 finding from 1 review

Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 436 participants
Low

Intervention not reported

Adverse events · Patients with brain metastases

1 finding from 1 review

Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 568 participants
Low

Intervention not reported

5‐ year OS · women with stage III or IV endometrial cancer after primary cytoreductive surgery

The intervention probably leads to lower 5‐ year OS (moderate certainty).

1 finding from 1 review

Adjuvant chemotherapy for advanced endometrial cancer 2014 · Cochrane Headline outcomes only
HR 0.75 [0.57, 0.99]
2 studies · 620 participants
Moderate

Intervention not reported

5‐year PFS · women with stage III or IV endometrial cancer after primary cytoreductive surgery

The intervention probably leads to lower 5‐year PFS (moderate certainty).

1 finding from 1 review

Adjuvant chemotherapy for advanced endometrial cancer 2014 · Cochrane Headline outcomes only
HR 0.74 [0.59, 0.92]
2 studies · 620 participants
Moderate

Intervention not reported

5‐year OS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery

The intervention showed no clear difference in 5‐year OS (stage III) (moderate certainty).

1 finding from 1 review

Adjuvant chemotherapy for advanced endometrial cancer 2014 · Cochrane Headline outcomes only
HR 0.76 [0.57, 1.02]
2 studies · 514 participants
Moderate

Intervention not reported

5‐year PFS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery

The intervention showed no clear difference in 5‐year PFS (stage III) (moderate certainty).

1 finding from 1 review

Adjuvant chemotherapy for advanced endometrial cancer 2014 · Cochrane Headline outcomes only
HR 0.81 [0.63, 1.05]
2 studies · 514 participants
Moderate

Summary of findings: EBRT vs no EBRT

Death from all causes · women with stage I endometrial cancer

Summary of findings: EBRT showed no clear difference in death from all causes compared with no EBRT (moderate certainty).

1 finding from 1 review

Adjuvant radiotherapy for stage I endometrial cancer 2012 · Cochrane Headline outcomes only
HR 0.99 [0.82, 1.2]
2628 participants
Moderate

Summary of findings: EBRT vs no EBRT

Endometrial carcinoma‐related death · women with stage I endometrial cancer

Summary of findings: EBRT showed no clear difference in endometrial carcinoma‐related death compared with no EBRT (moderate certainty).

1 finding from 1 review

Adjuvant radiotherapy for stage I endometrial cancer 2012 · Cochrane Headline outcomes only
HR 0.96 [0.72, 1.28]
2965 participants
Moderate